Oaxaca Site Management Organization

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Metastatic breast cancer3 trials
• Lung cancer2 trials
• Prostate cancer2 trials
• Colorectal cancer1 trial
• Crohn's disease1 trial
• Idiopathic pulmonary fibrosis1 trial
• Liver and biliary tract cancer1 trial
• Lupus (SLE)1 trial
• Sarcoma1 trial

Phase

• Phase 25 trials
• Phase 34 trials

Status

• Active, not recruiting6 trials
• Completed2 trials
• Recruiting1 trial

Lead sponsor

• Eli Lilly and Company2 trials
• Pfizer2 trials
• Gilead Sciences1 trial
• Hoffmann-La Roche1 trial
• Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)1 trial
• and 2 more

Running trials

• Active, not recruiting

  A Study of Obexelimab in Patients With Systemic Lupus Erythematosus

  NCT06559163· Phase 2· Zenas BioPharma (USA), LLC· Source

• Recruiting

  A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

  NCT06226883· Phase 2· Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)· Source

  Contact: Ana Vera Heredia (principal investigator)

• Active, not recruiting

  Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer

  NCT05502237· Phase 3· Gilead Sciences· Source

• Active, not recruiting

  LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05321420· Phase 2· PureTech· Source

• Active, not recruiting

  A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

  NCT04975308· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

  NCT04821622· Phase 3· Pfizer· Source

• Recruiting

  Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

  NCT04557449· Phase 2· Pfizer· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Crohn's disease1 recruiting

Closed trials

• Completed

  A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation

  NCT04102098· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer

  NCT02747004· Phase 2· Eli Lilly and Company· Source